Home › Compound Library › LL-37
Immune defence and barrier
LL-37: Your Own Antimicrobial Peptide, With Real Trial Data Behind It
The short answer
LL-37 is the only cathelicidin the human body makes: a 37-amino-acid peptide that punctures bacterial membranes and, separately, directs the immune cells that clean up and rebuild afterwards. It has been through randomised controlled trials in hard-to-heal wounds, which is more than most compounds in this library can say.
Questions people ask about LL-37
LL-37 at a glance
| Also called | Human cathelicidin; hCAP-18 is the precursor protein it is cut from |
|---|---|
| What it is | A 37-amino-acid peptide, the only cathelicidin produced by humans |
| Acts on | Microbial membranes directly; immune cell recruitment, wound repair and blood vessel growth |
| Main system | Innate immunity: skin, gut and airway barriers |
| Evidence level | Randomised controlled human trials in venous leg ulcers, applied topically |
| FDA status (Oct 2026) | Not approved. It was not among the peptides the July 2026 advisory committee recommended |
| In sport | Not named on the 2026 WADA prohibited list |
What is LL-37?
Your immune system has a fast layer that does not need to learn anything first. Antimicrobial peptides are part of it, sitting on skin, in the gut lining and in the airways, ready before any infection is recognised. LL-37 is the human member of the cathelicidin family, and the only one.
It is cut from a larger protein called hCAP-18 when it is needed. The name describes it literally: it begins with two leucines and is 37 amino acids long.
Vitamin D is part of this story. The gene that produces LL-37 is regulated in part by vitamin D, which is one of the mechanisms behind the link between vitamin D status and infection risk.
Regenerative Resilience profiles it at pp. 132–134, The Cognitive Advantage at pp. 199–203, and Targeted Peptide Systems at pp. 147–149.
How does LL-37 work?
It does two different jobs, and conflating them is where most of the confusion about this compound comes from.
- Direct killing. LL-37 carries a positive charge and is attracted to the negatively charged membranes of bacteria. It inserts itself and disrupts the membrane physically. Because that is a structural attack rather than a biochemical one, it works against bacteria, some fungi and some enveloped viruses, and resistance is harder to develop against it.
- Direction. Separately, it acts as a signal: recruiting immune cells to the site, influencing which inflammatory messengers are produced, promoting the growth of new blood vessels, and supporting the cells that close a wound.
The second job is why it is studied for healing rather than only for infection. Regenerative Resilience (pp. 132–134) places it among the immune-modulating compounds for that reason, alongside KPV, which works on inflammation from the opposite direction.
What does the research show?
This is the part that sets LL-37 apart in this library: it has randomised controlled trial data in people. A multicentre, prospective, randomised trial of topical LL-37 in hard-to-heal venous leg ulcers was published in Wound Repair and Regeneration in 2021 (reference 1), following an earlier controlled trial published in the same journal in 2014 that reported the treatment was safe and enhanced healing (reference 2).
Note the route. Both trials applied it to the wound. That is the form the human evidence covers, and it is not the same as injecting it or taking it systemically, which have not been tested the same way.
The wider literature is large and mostly laboratory-based, covering antimicrobial activity against resistant organisms, barrier function in the gut and airways, and the vitamin D connection.
Where the evidence stands. For topical use in difficult wounds, there is genuine controlled human data. For the systemic uses it is discussed for, including chronic infection, gut barrier problems and immune support generally, the reasoning runs from mechanism and laboratory work rather than from trials.
Side effects and cautions
In the wound-healing trials the treatment was reported as safe and well tolerated, applied topically to the affected area.
The caution that belongs on this page is about concentration rather than about the molecule. LL-37 works by disrupting membranes, and at high enough concentrations that activity is not perfectly selective for microbial membranes. This is a peptide the body produces in controlled amounts, in specific places, at specific times, and that context is part of how it stays safe.
The practical risks are the familiar ones for anything sold outside a regulated supply chain: purity, sterility and identity depend on the supplier.
Active infection is a medical problem with treatments that work. If something is infected, that deserves a clinician and a diagnosis, not a research peptide in place of one.
Is LL-37 legal or FDA approved?
Not approved. There is no approved LL-37 product, and it was not among the six peptides the FDA advisory committee recommended for compounding in July 2026 (references 3, 4).
Sport: LL-37 is not named on the 2026 WADA prohibited list. Athletes should check with their own governing body, since lists are updated annually.
This page is reviewed and updated as the status changes.
LL-37 vs KPV, thymosin alpha-1 and the other immune compounds
Regenerative Resilience (p. 76) sets out the rule these comparisons hang on: match the compound to the failure you have actually identified.
- vs KPV: opposite directions. KPV damps an inflammatory signal that is running too hot. LL-37 recruits and directs immune activity. Using one where the other is needed is the mistake worth avoiding.
- vs thymosin alpha-1: thymosin alpha-1 works upstream on how the adaptive immune system is trained and directed, with decades of clinical use behind it. LL-37 is innate immunity, faster and more local.
- vs BPC-157: both come up for wound healing, by different routes. BPC-157 works largely through new blood vessel growth; LL-37 handles the microbial side and recruits the cells that do the rebuilding.
Our article on the immune rules most protocols ignore covers how the books decide between them.
Risk, benefit, and the conversation this page is for
LL-37 is one of the few compounds in this library with randomised controlled human data behind it. Two controlled trials in hard-to-heal venous leg ulcers reported it safe and effective, applied to the wound. That is a stronger starting position than most of this library, and it comes with a boundary worth stating plainly: the evidence covers the topical route and that use. For the systemic uses it gets discussed for, the reasoning runs from mechanism and laboratory work, where the toxicology has stayed quiet and the trials have not been done.
The regulatory picture is moving, and it is moving one compound at a time. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. The same committee has turned peptides down and still does: ipamorelin and CJC-1295 sit in Category 2, barred from compounding. The distinction is the useful part. Each compound is being read on its own risk record rather than lumped under one verdict called unapproved.
The clinicians working with these compounds are not fringe, and their reasoning is comparative rather than enthusiastic. The approved options for chronic inflammation and slow-healing tissue carry burdens that are thoroughly documented: long-term anti-inflammatories on the gut and kidneys, repeated corticosteroid injections on connective tissue, glucose control and bone. Weighed against that, a compound with a quiet toxicology record and an incomplete efficacy record is a reasonable thing to discuss. It is not a reasonable thing to promise, and that is the line this page tries to hold.
Which is the point of the series. Nothing here is a recommendation to use LL-37. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
LL-37: frequently asked questions
What is LL-37?
The only cathelicidin the human body produces: a 37-amino-acid antimicrobial peptide that disrupts microbial membranes and also directs immune repair.
What is LL-37 used for?
In controlled human trials, topical treatment of hard-to-heal venous leg ulcers (references 1, 2). It is discussed more widely for infection and barrier problems, which rests on laboratory work rather than trials.
Is LL-37 FDA approved?
No. There is no approved product, and it was not among the six peptides the July 2026 advisory committee recommended for compounding.
How does LL-37 kill bacteria?
Physically. It carries a positive charge, is drawn to negatively charged bacterial membranes, and disrupts them structurally, which makes resistance harder to develop than against most antibiotics.
Is LL-37 related to vitamin D?
Yes. The gene that produces LL-37 is regulated in part by vitamin D, which is one mechanism behind the link between vitamin D status and infection risk.
LL-37 vs KPV: which one?
They pull in opposite directions. KPV damps inflammation; LL-37 recruits and directs immune activity. The choice depends on which failure you have identified.
What are LL-37’s side effects?
In the wound trials it was reported as safe and well tolerated topically. The caution is concentration: membrane disruption is not perfectly selective at high levels, and the body produces this peptide in controlled amounts in specific places.
Is LL-37 banned in sport?
It is not named on the 2026 WADA prohibited list. Check with your sport’s governing body, as lists change each year.
Where LL-37 appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how LL-37 fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how LL-37 fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Mahlapuu M, Sidorowicz A, Mikosinski J, et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen. 2021;29(6):938–950. View sourceRandomised controlled trial, topical
- Grönberg A, Mahlapuu M, Ståhle M, Mörgelin M, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014;22(5):613–621. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. LL-37 is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.